Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 5/20 | 0.45 |
| ▸ | CA1 | P00915 | 5/20 | 0.45 |
| ▸ | CA9 | Q16790 | 5/20 | 0.45 |
| ▸ | LIG1 | P18858 | 1/20 | 0.44 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | HBB | P68871 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3822490 | 0.96 | HPGD (0.49) | HPGDTSHRHSD17B10MAPK1CA12 | |
| SCHEMBL17747107 | 0.85 | HPGD (0.44) | HPGDTSHRHSD17B10MAPK1CA12 | |
| SCHEMBL20537236 | 0.83 | HPGD (0.47) | HPGDTSHRHSD17B10MAPK1CA12 | |
| SCHEMBL20554924 | 0.83 | HPGD (0.43) | HPGDTSHRHSD17B10MAPK1CA12 | |
| SCHEMBL28406921 | 0.82 | CA12 (0.55) | HPGDMAPK1CA12CA1CA9 | |
| SCHEMBL17747138 | 0.80 | CASP1 (0.53) | HPGDTSHRHSD17B10MAPK1CA12 | |
| Anthracene SCHEMBL28197514 | 0.79 | CYP3A4 (0.41) | HPGDTSHRHSD17B10MAPK1CA12 | |
| 1,2-Diallyloxybenzene SCHEMBL29768784 | 0.78 | HPGD (0.60) | HPGDTSHRHSD17B10MAPK1CA12 | |
| 1,2-Diallyloxybenzene SCHEMBL366516 | 0.78 | HPGD (0.60) | HPGDTSHRHSD17B10MAPK1CA12 | |
| SCHEMBL5413465 | 0.78 | HPGD (0.49) | HPGDTSHRHSD17B10MAPK1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560587-B2 | Bis[urea-urethane] compounds | XEROX CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-7504502-B2 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080171877-A1 | GUANIDINOPYRIMIDINONE COMPOUNDS AND PHASE CHANGE INKS CONTAINING SAME | XEROX CORPORATION (US) | 2008-07-17 | — | — | US | disclosed |
| US-7371858-B2 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-7317122-B2 | Curable trans-1,2-cyclohexane bis(urea-urethane) compounds | XEROX CORPORATION (US) | 2008-01-08 | — | — | US | disclosed |
| US-7314949-B2 | 1,2-bis(6-(ethylhexyloxycarbonylamino)hexylaminocarbonylamino)cyclohexane; gelling agents for hot melt and phase change inks | XEROX CORPORATION (US) | 2008-01-01 | — | — | US | disclosed |
| US-7220300-B2 | Phase change inks containing bis(urea-urethane) compounds | XEROX CORPORATION (US) | 2007-05-22 | — | — | US | disclosed |
| US-7157601-B2 | Alkylated urea and triaminotriazine compounds and phase change inks containing same | XEROX CORPORATION (US) | 2007-01-02 | — | — | US | disclosed |
| US-7153349-B2 | Phase change inks containing curable trans-1,2-cyclohexane bis(urea-urethane) compounds | XEROX CORPORATION (US) | 2006-12-26 | — | — | US | disclosed |
| US-7144450-B2 | Phase change inks containing trans-1,2-cyclohexane bis(urea-urethane) compounds | XEROX CORPORATION (US) | 2006-12-05 | — | — | US | disclosed |
| US-6860928-B2 | Alkylated urea and triaminotriazine compounds and phase change inks containing same | XEROX CORPORATION (US) | 2005-03-01 | — | — | US | disclosed |
| US-6835833-B2 | Alkylated tetrakis(triaminotriazine) compounds and phase change inks containing same | XEROX CORPORATION | 2004-12-28 | — | — | US | disclosed |
| US-20040249210-A1 | Alkylated urea and triaminotriazine compounds and phase change inks containing same | XEROX CORPORATION | 2004-12-09 | — | — | US | disclosed |
| US-6811595-B2 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION | 2004-11-02 | — | — | US | disclosed |
| US-20040158063-A1 | Alkylated tetrakis(triaminotriazine) compounds and phase change inks containing same | XEROX CORPORATION | 2004-08-12 | — | — | US | disclosed |
| US-6761758-B2 | INK COMPOSITION COMPRISING COLORANT AND PHASE CHANGE INK CARRIER; INK JET PRINTING | XEROX CORPORATION | 2004-07-13 | — | — | US | disclosed |
| US-20040075723-A1 | Alkylated urea and triaminotriazine compounds and phase change inks containing same | XEROX CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20040065227-A1 | Phase change inks containing gelator additives | XEROX CORPORATION | 2004-04-08 | — | — | US | disclosed |
| US-20040060474-A1 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION | 2004-04-01 | — | — | US | disclosed |
| US-20040050295-A1 | ALKYLATED TETRAKIS(TRIAMINOTRIAZINE) COMPOUNDS AND PHASE CHANGE INKS CONTAINING SAME | XEROX CORPORATION | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040060474-A1 | Guanidinopyrimidinone compounds and phase change inks containing same | CCNI, INO80, CCNY | HPGD 3309/4885TSHR 3461/4885HSD17B10 961/4885 |
| US-20040050295-A1 | ALKYLATED TETRAKIS(TRIAMINOTRIAZINE) COMPOUNDS AND PHASE CHANGE INKS CONTAINING SAME | CCNT1, CCNT2, CCNK | HPGD 4441/4885TSHR 1463/4885HSD17B10 4216/4885 |
| US-20080171877-A1 | GUANIDINOPYRIMIDINONE COMPOUNDS AND PHASE CHANGE INKS CONTAINING SAME | INO80, RPP30, RO60 | HPGD 3467/4885TSHR 2131/4885HSD17B10 1142/4885 |
| US-20040158063-A1 | Alkylated tetrakis(triaminotriazine) compounds and phase change inks containing same | CCNT1, CCNT2, CCNK | HPGD 4441/4885TSHR 1463/4885HSD17B10 4216/4885 |
| US-20040249210-A1 | Alkylated urea and triaminotriazine compounds and phase change inks containing same | NR4A1, NR0B1, RCOR1 | HPGD 4736/4885TSHR 524/4885HSD17B10 3089/4885 |
| US-20040075723-A1 | Alkylated urea and triaminotriazine compounds and phase change inks containing same | NR4A1, NR1I3, CCNY | HPGD 4576/4885TSHR 748/4885HSD17B10 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.